For sure pharmaceutical companies made hundreds of billions of dollars during the COVID pandemic on their experimental shots, mostly mRNA creations that actually were “treatments” more than “vaccines,” and ultimately have proven to carry with them a multitude of side effects, including multiple side effects that are fatal.
But now a newly released study from Germany, a peer-reviewed assessment, has shown that a cheap nasal spray, going for maybe $10 a bottle, used three times a day is mostly effective at stopping the China virus.
The study appeared in the JAMA Internal Medicine publication and was cited in a report in the Gateway Pundit.
That report said, “For years, Americans were told their only hope was to roll up their sleeves for Pfizer, Moderna, and the rest of the vaccine cartel. Trillions of dollars flowed into their coffers while dissenting doctors were silenced, families were divided, and countless workers lost their jobs under vaccine mandates.”
But, it said, now the study of azelastine nasal spray confirmed it reduced COVID infections by two-thirds.
The JAMA publication confirmed, “In this randomized placebo-controlled clinical trial that included 450 participants, the incidence of laboratory-confirmed SARS-CoV-2 infections was significantly lower with application of azelastine nasal spray compared with placebo treatment.”
The spray already has been in use “for decades to treat allergic rhinitis,” and “has in vitro antiviral activity against respiratory viruses, including SARS-CoV-2,” JAMA reported.
“A phase 2, double-blind, placebo-controlled, single-center trial was conducted from March 2023 to July 2024. Healthy adults from the general population were enrolled at the Saarland University Hospital in Germany,” it explained. “Participants were randomly assigned 1:1 to receive azelastine, 0.1%, nasal spray or placebo 3 times daily for 56 days. SARS-CoV-2 rapid antigen testing (RAT) was conducted twice weekly, with positive results confirmed by polymerase chain reaction (PCR). Symptomatic participants with negative RAT results underwent multiplex PCR testing for respiratory viruses.”
The study had 227 patients assigned to azelastine and 223 to placebo treatment.
“In the intention-to-treat (ITT) population, the incidence of PCR-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group (n = 5 [2.2%]) compared with the placebo group (n = 15 [6.7%]).
“As secondary end points, azelastine demonstrated an increase in mean (SD) time to SARS-CoV-2 infection among infected participants (31.2 [9.3] vs 19.5 [14.8] days), a reduction of the overall number of PCR-confirmed symptomatic infections (21 of 227 participants vs 49 of 223 participants), and a lower incidence of PCR-confirmed rhinovirus infections (1.8% vs 6.3%),” the report said.
The study was done at Saarland University Hospital in Germany.
The reduction in risk of infection amounted to 67%.
“Not only were fewer people infected, but those who did get sick had longer protection before infection (31 days on average versus 19 days in the placebo group) and shorter illness duration when measured by rapid tests (3.4 days vs 5.1 days),” the Gateway Pundit explained.
“The spray didn’t just block COVID. It also: Cut symptomatic SARS-CoV-2 infections from 6.3% (placebo) down to 1.8%. Reduced rhinovirus (common cold) infections from 6.3% to 1.8%. Slashed the overall number of PCR-confirmed infections (COVID + other respiratory viruses) from 22% in placebo to 9.3% with azelastine.”
